Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome

Lea Guerrini-Rousseau, Jane Merlevede, Philippe Denizeau, Felipe Andreiuolo, Pascale Varlet, Stéphanie Puget, Kevin Beccaria, Thomas Blauwblomme, Odile Cabaret, Nadim Hamzaoui, Franck Bourdeaut, Cécile Faure-Conter, Martine Muleris, Chrystelle Colas, Tiphaine Adam De Beaumais, David Castel, Etienne Rouleau, Laurence Brugières, Jacques Grill, Marie Anne Debily

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    Résumé

    Background: Constitutional mismatch repair deficiency (CMMRD) is a cancer predisposition due to biallelic mutations in one of the mismatch repair (MMR) genes associated with early onset of cancers, especially high-grade gliomas. Our aim was to decipher the molecular specificities of these gliomas. Methods: Clinical, histopathological, and whole exome sequencing data were analyzed in 12 children with genetically proven CMMRD and a high-grade glioma. Results: PDL1 expression was present in immunohistochemistry in 50% of the samples. In 9 patients, the glioma harbored an ultra-hypermutated phenotype (104-635 coding single nucleotide variants (SNV) per Mb, median 204). Driver mutations in POLE and POLD1 exonuclease domains were described for 8 and 1 patients respectively and were always present in the mutation burst with the highest variant allele frequency (VAF). The mutational signatures were dominated by MMR-related ones and similar in the different mutation bursts of a same patient without subsequent enrichment of the mutation signatures with POL-driven ones. Median number of coding SNV with VAF above one of the driving polymerase mutation per Mb was 57 (17-191). Our findings suggest that somatic polymerase alterations does not entirely explain the ultra-hypermutant phenotype. SETD2, TP53, NF1, EPHB2, PRKDC, and DICER1 genes were frequently mutated with higher VAF than the deleterious somatic polymerase mutation. Conclusions: CMMRD-associated gliomas have a specific oncogenesis that does not involve usual pathways and mutations seen in sporadic pediatric or adult glioblastomas. Frequent alterations in other pathways such as MAPK may suggest the use of other targeted therapies along with PD1 inhibitors.

    langue originaleAnglais
    Numéro d'articlevdae120
    journalNeuro-Oncology Advances
    Volume6
    Numéro de publication1
    Les DOIs
    étatPublié - 1 janv. 2024

    Contient cette citation